The estimated Net Worth of David M Goldstein is at least 126 千$ dollars as of 10 August 2020. David Goldstein owns over 6,000 units of Principia Biopharma stock worth over 125,860$ and over the last 5 years David sold PRNB stock worth over 0$.
David has made over 4 trades of the Principia Biopharma stock since 2019, according to the Form 4 filled with the SEC. Most recently David exercised 6,000 units of PRNB stock worth 18,660$ on 10 August 2020.
The largest trade David's ever made was exercising 10,000 units of Principia Biopharma stock on 7 November 2019 worth over 18,800$. On average, David trades about 4,667 units every 46 days since 2019. As of 10 August 2020 David still owns at least 37,739 units of Principia Biopharma stock.
You can see the complete history of David Goldstein stock trades at the bottom of the page.
David's mailing address filed with the SEC is C/O PRINCIPIA BIOPHARMA INC., 220 E. GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 6 years, insiders at Principia Biopharma have traded over 44,614,108$ worth of Principia Biopharma stock and bought 1,381,884 units worth 39,224,700$ . The most active insiders traders include Plc Gsk、Patrick Machado、Partners L P/Ilbiotechnolog.... On average, Principia Biopharma executives and independent directors trade stock every 17 days with the average trade being worth of 330,499$. The most recent stock trade was executed by Roy C. Hardiman on 18 September 2020, trading 5,000 units of PRNB stock currently worth 29,300$.
Principia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immune-mediated diseases. The company is developing rilzabrutinib, an inhibitor that is in Phase III clinical trials for the treatment of pemphigus, a chronic skin disease, as well as and pemphigus foliaceus; in a Phase 1/2 trial for the treatment of immune thrombocytopenia; and a Phase 2 trial for the treatment of IgG4-related disease. It is also developing PRN2246/SAR442168, an inhibitor, which is in Phase Ii clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; and PRN473, a drug candidate that is in Phase I clinical trial for the treatment of immune-medicated diseases. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California.
Principia Biopharma executives and other stock owners filed with the SEC include: